CA2676841C - Controlled release of actives in skin - Google Patents

Controlled release of actives in skin Download PDF

Info

Publication number
CA2676841C
CA2676841C CA2676841A CA2676841A CA2676841C CA 2676841 C CA2676841 C CA 2676841C CA 2676841 A CA2676841 A CA 2676841A CA 2676841 A CA2676841 A CA 2676841A CA 2676841 C CA2676841 C CA 2676841C
Authority
CA
Canada
Prior art keywords
agents
skin
active compound
group
nanospheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2676841A
Other languages
English (en)
French (fr)
Other versions
CA2676841A1 (en
Inventor
Joachim B. Kohn
Bozena Michniak
David Devore
Larisa Sheihet
Prafulla Chandra
Priya Batheja
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of CA2676841A1 publication Critical patent/CA2676841A1/en
Application granted granted Critical
Publication of CA2676841C publication Critical patent/CA2676841C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/90Block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00Anti-perspirants or body deodorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/04Preparations for care of the skin for chemically tanning the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/02Preparations for cleaning the hair
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/12Preparations containing hair conditioners
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41Particular ingredients further characterized by their size
    • A61K2800/412Microsized, i.e. having sizes between 0.1 and 100 microns
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41Particular ingredients further characterized by their size
    • A61K2800/413Nanosized, i.e. having sizes below 100 nm
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Birds (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2676841A 2007-01-31 2008-01-31 Controlled release of actives in skin Active CA2676841C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88755307P 2007-01-31 2007-01-31
US60/887,553 2007-01-31
PCT/US2008/052728 WO2008095144A2 (en) 2007-01-31 2008-01-31 Controlled release of actives in skin

Publications (2)

Publication Number Publication Date
CA2676841A1 CA2676841A1 (en) 2008-08-07
CA2676841C true CA2676841C (en) 2017-09-26

Family

ID=39674804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2676841A Active CA2676841C (en) 2007-01-31 2008-01-31 Controlled release of actives in skin

Country Status (8)

Country Link
US (1) US8414871B2 (de)
EP (2) EP3542785A1 (de)
CN (1) CN101668512A (de)
AU (1) AU2008210329B2 (de)
CA (1) CA2676841C (de)
MX (1) MX2009008030A (de)
NZ (1) NZ578693A (de)
WO (1) WO2008095144A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120048003A1 (en) * 2010-08-24 2012-03-01 GOLDEN PRODUCTS LLC, Limited Liability Company Vitamin assay methods
CN102706971A (zh) * 2010-12-09 2012-10-03 江南大学 一种以离子液体作为添加剂的反向微乳毛细管电动色谱分析化妆品中的糖皮质激素的方法
US9549891B2 (en) 2012-03-19 2017-01-24 The Procter & Gamble Company Superabsorbent polymers and sunscreen actives for use in skin care compositions
PL2897620T3 (pl) * 2012-09-21 2020-11-02 Intensity Therapeutics, Inc Sposób leczenia nowotworu złośliwego
WO2014116716A1 (en) * 2013-01-22 2014-07-31 Rutgers, The State University Of New Jersey Biocompatible polymer compositions for tissue void filling
US11000472B2 (en) 2015-04-06 2021-05-11 Lg Household & Health Care Ltd. Soluble microneedle for delivering poorly-soluble drug
US10285926B2 (en) 2015-06-29 2019-05-14 The Procter & Gamble Company Superabsorbent polymers and starch powders for use in skin care compositions
WO2017155267A1 (ko) 2016-03-07 2017-09-14 성균관대학교산학협력단 자가 조립 나노입자 방출형 용해성 마이크로니들 구조체 및 그 제조방법
KR101956444B1 (ko) * 2016-03-07 2019-03-08 성균관대학교산학협력단 자가 조립 나노입자 방출형 용해성 마이크로니들 구조체 및 그 제조방법
WO2018002153A1 (en) 2016-06-28 2018-01-04 Assistance Publique - Hopitaux De Paris Hycanthone derivatives and primaquine derivatives for use in the prevention and/or the treatment of disorders associated to gammaherpesvirus
FI3541362T3 (fi) 2016-11-15 2026-02-05 Klaria Pharma Holding Ab Triptaania käsittävä alginaattikalvo
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
EP3795976A4 (de) * 2018-05-17 2022-03-02 Shiseido Company, Ltd. Klebstoffzusammensetzung zum sammeln von stratum corneum, instrument zum sammeln von stratum corneum, biomaterialextraktionskit und biomaterialsammelverfahren
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
BR112022004315A2 (pt) * 2019-10-18 2022-06-21 Unilever Ip Holdings B V Método para medir as propriedades de enxágue de uma composição de uma superfície

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980449A (en) 1988-07-14 1990-12-25 Rutgers, The State University Polyiminocarbonate synthesis
US5587507A (en) 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
US5099060A (en) 1990-06-12 1992-03-24 Rutgers, The State University Of New Jersey Synthesis of amino acid-derived bioerodible polymers
US5216115A (en) 1990-06-12 1993-06-01 Rutgers, The State University Of New Jersey Polyarylate containing derivatives of the natural amino acid L-tyrosine
US5658995A (en) * 1995-11-27 1997-08-19 Rutgers, The State University Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide)
US6120491A (en) 1997-11-07 2000-09-19 The State University Rutgers Biodegradable, anionic polymers derived from the amino acid L-tyrosine
AU737151B2 (en) * 1997-11-07 2001-08-09 Rutgers, The State University Radio-opaque polymeric biomaterials government license rights
US6468980B1 (en) * 2000-09-01 2002-10-22 Oxycal Laboratories, Inc. Methods and compositions for potentiating cancer chemotherapeutic agents
FR2830773B1 (fr) * 2001-10-11 2004-07-23 Oreal Utilisation de copolymeres amphiphiles pour stabiliser des dispersions de composes organiques insolubles filtrant le rayonnement uv, dispersions stabilisees par ces copolymeres et compositions cosmetiques les contenant
US8591951B2 (en) * 2002-05-15 2013-11-26 Joachim B. Kohn Tri-block copolymers for nanosphere-based drug delivery
CN100503673C (zh) * 2005-07-07 2009-06-24 复旦大学 具有疏水核心、亲水表面的纳米粒及其制备方法和应用

Also Published As

Publication number Publication date
EP2114377A2 (de) 2009-11-11
AU2008210329B2 (en) 2013-11-28
NZ578693A (en) 2011-08-26
EP2114377A4 (de) 2012-08-01
EP2114377B1 (de) 2018-10-17
MX2009008030A (es) 2009-10-19
EP3542785A1 (de) 2019-09-25
CN101668512A (zh) 2010-03-10
US20090317472A1 (en) 2009-12-24
CA2676841A1 (en) 2008-08-07
US8414871B2 (en) 2013-04-09
AU2008210329A1 (en) 2008-08-07
WO2008095144A2 (en) 2008-08-07
WO2008095144A3 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
CA2676841C (en) Controlled release of actives in skin
Yin et al. Physicochemical aspects of doxorubicin-loaded pH-sensitive polymeric micelle formulations from a mixture of poly (L-histidine)-b-poly (L-lactide)-b-poly (ethylene glycol)
Ko et al. Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly (β-amino ester) block copolymer micelles for cancer therapy
EP3139909B1 (de) Mit hyperverzweigtem polyglycerin beschichtete partikeln
Le Garrec et al. Optimizing pH-responsive polymeric micelles for drug delivery in a cancer photodynamic therapy model
Wang et al. Biodegradable functional polycarbonate micelles for controlled release of amphotericin B
Wang et al. Polymeric micelles with a pH-responsive structure as intracellular drug carriers
AU675211B2 (en) Enhanced skin penetration system for improved topical delivery of drugs
Sheihet et al. Tyrosine-derived nanospheres for enhanced topical skin penetration
Giulbudagian et al. Correlation between the chemical composition of thermoresponsive nanogels and their interaction with the skin barrier
Kontogiannopoulos et al. Chimeric advanced drug delivery nano systems (chi-aDDnSs) for shikonin combining dendritic and liposomal technology
Pourmanouchehri et al. Controlled release of 5-fluorouracil to melanoma cells using a hydrogel/micelle composites based on deoxycholic acid and carboxymethyl chitosan
Bagby et al. Lymphatic trafficking kinetics and near-infrared imaging using star polymer architectures with controlled anionic character
Faiz et al. Pioglitazone-loaded nanostructured lipid carriers: In-vitro and in-vivo evaluation for improved bioavailability
Sallam et al. Mechanistic analysis of human skin distribution and follicular targeting of adapalene-loaded biodegradable nanospheres with an insight into hydrogel matrix influence, in vitro skin irritation, and in vivo tolerability
Zhang et al. A PEGylated alternating copolymer with oxidation-sensitive phenylboronic ester pendants for anticancer drug delivery
Teixeira et al. Retinyl palmitate polymeric nanocapsules as carriers of bioactives
WO2021119464A1 (en) Compositions and modular nano- and microparticles for the delivery of various agents and use thereof
Stefani et al. Hyperbranched glycerol-based core-amphiphilic branched shell nanotransporters for dermal drug delivery
Zabihi et al. Non-ionic PEG-oligoglycerol dendron conjugated nano-carriers for dermal drug delivery
Odrobińska et al. Retinol derivative as bioinitiator in the synthesis of hydroxyl-functionalized polymethacrylates for micellar delivery systems.
KR100967113B1 (ko) 코엔자임 q10을 함유한 자기회합성 고분자 나노입자 및이를 함유한 피부 외용제 조성물
HK1138789A (en) Controlled release of actives in skin
WO2012049453A2 (en) Compositions for topical applications
Asadi et al. Recent advances in bioactive materials for diagnosis and treatment of oral cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130131

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250124

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260318